The Company | Our Team
We are a global women’s health company focused on offering innovative, science led, diagnostic technologies that overcome the limitations of standard anatomical imaging (which include digital X-Ray mammography, tomography/3D mammography and ultrasound). Our technology allows for earlier detection of breast cancer in women at greater risk due to having dense breast tissue as well as familial and genetic risk factors.
Mammography is the screening modality of choice for women who have fatty or scattered density; however, more than 45% of women undergoing mammography have dense breast tissue. Due to the opaque nature of dense breast mammography images, the ability to screen women with dense breast tissue effectively is limited as dense tissue and cancer often appear the same on a mammogram and 3D mammography. What you cannot see, you are most likely are not going to detect.
LumaGEM® Molecular Breast Imaging (MBI) allows radiologists to utilize a functional approach and see past the density that the anatomical approaches are often limited by. By aligning the most innovative imaging technologies that are best suited to the patient’s needs, we are enabling women to receive their care through a personalized medicine approach. Improved detection rates (~400% increase in invasive cancer detection rate) and reduction in biopsies (50%)1 result in improved patient experience as the images can be interpreted at the time of study, alleviating anxiety while awaiting results post examination. This leads to better patient outcomes, lower healthcare costs and improved patient experience.
Gamma Medica is committed to providing peace of mind to patients and physicians alike through the use of MBI as a secondary screening and diagnostic tool.
Philip Croxford, President and CEO
Gamma Medica, Inc.
Gamma Medica, Inc. is a proud member of: